Loading
A phase 3 trial of aumolertinib in lung cancer, run by Qianfoshan Hospital, now recruiting.
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance is a phase 3, interventional study registered as NCT06043973 by Qianfoshan Hospital, with a registry enrolment figure of 98 participants, started 2023-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: almonertinib. Conditions listed: Advanced Non-small Cell Lung Cancer. Primary outcome: PFS. Lung eligibility wording from the registry: "Metastatic Non-squamous NSCLC is histologically or cytologically proven to be inoperable and cannot receive radical concurrent chemoradiotherapy". Sites: China. No results are recorded here; the registry entry is the source.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.